Characterization of NMO and NMOSD Patients with a Late Onset

Characterization of NMO and NMOSD Patients with a Late Onset

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Collongues, N, Marignier, R, Jacob, A, Siva, A, Paul, F, Zephir, H, Leite, M, Akman-Demir, G, Elsone, L, Jarius, S, Papeix, C, Mutch, K, Saip, S, Wildemann, B, Kitley, J, Karabudak, R, Aktas, O, Kuscu, D, Altintas, A, Palace, J, Confavreux, C, De Seze, J
Μορφή:	Journal article
Έκδοση:	2013

Παρόμοια τεκμήρια

Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.
ανά: Collongues, N, κ.ά.
Έκδοση: (2013)

RELAPSING AQP4 ANTIBODY NEGATIVE NMO WITH MOG ANTIBODIES
ανά: Elsone, L, κ.ά.
Έκδοση: (2014)

NMO-IgG in the diagnosis of neuromyelitis optica.
ανά: Jarius, S, κ.ά.
Έκδοση: (2007)

Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes
ανά: Juryńczyk, M, κ.ά.
Έκδοση: (2015)

Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab.
ανά: Kitley, J, κ.ά.
Έκδοση: (2014)

Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab
ανά: Kitley, J, κ.ά.
Έκδοση: (2014)

A novel sensitive assay for aqueporin-4 antibodies (NMO-IgG)
ανά: Waters, P, κ.ά.
Έκδοση: (2007)

Glycine receptor antibody — a marker for NMO/ NON-MS demyelination?
ανά: Hamid, S, κ.ά.
Έκδοση: (2015)

Revised diagnostic criteria for neuromyelitis optica--incorporation of NMO-IgG status.
ανά: Jarius, S, κ.ά.
Έκδοση: (2007)

Resting-state functional MRI demonstrates brain network reorganization in neuromyelitis optica spectrum disorder (NMOSD).
ανά: Kévin Bigaut, κ.ά.
Έκδοση: (2019-01-01)

MOG-IGG IN NMO AND NMO-LIKE DISORDERS
ανά: Luppe, S, κ.ά.
Έκδοση: (2014)

LONG TERM OUTCOME IN NEUROMYELITIS OPTICA: LESSONS FROM 6 YEARS OF THE UK NMO STUDY
ανά: Jacob, A, κ.ά.
Έκδοση: (2009)

Frequency of Aqp4-Ab in patients with neuromyelitis optica (Devic's syndrome) is higher than predicted by NMO-IgG testing
ανά: Jarius, S, κ.ά.
Έκδοση: (2007)

Spinal cord MRI features in neuromyelitis optica (NMO): characteristics and relationship with severity and recovery in longitudinally extensive transverse myelitis (LETM) attacks
ανά: Murchison, A, κ.ά.
Έκδοση: (2013)

Overlapping CNS inflammatory diseases: differentiating features of NMO and MS.
ανά: Juryńczyk, M, κ.ά.
Έκδοση: (2015)

Devic's neuromyelitis optica: Prognostic implications of NMO IgG status in Turkish patients
ανά: Akman-Demir, G, κ.ά.
Έκδοση: (2008)

A case of MS, ADEM, NMO or all three?
ανά: Pomeroy, I, κ.ά.
Έκδοση: (2005)

An audit of the diagnostic usefulness of the NMO-IgG assay for neuromyelitis optica
ανά: Littleton, E, κ.ά.
Έκδοση: (2006)

Real-life study to assess effectiveness and safety of eculizumab in patients with neuromyelitis optica spectrum disorders in France: protocol for ECUP4, an observational study
ανά: Romain Marignier, κ.ά.
Έκδοση: (2024-01-01)

Diagnosis of neuromyelitis optica (NMO) spectrum disorders: is MRI obsolete?
ανά: Downer, J, κ.ά.
Έκδοση: (2012)

Diagnosis of neuromyelitis optica (NMO) spectrum disorders: Is MRI obsolete?
ανά: Downer, J, κ.ά.
Έκδοση: (2012)

Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials.
ανά: Kitley, J, κ.ά.
Έκδοση: (2014)

Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials
ανά: Kitley, J, κ.ά.
Έκδοση: (2014)

NMO-IgG/Aqp4-Ab belongs to the IgG1 subclass and activates complement in vitro
ανά: Jarius, S, κ.ά.
Έκδοση: (2007)

Area postrema syndrome: Frequency, criteria, and severity in AQP4-IgG–positive NMOSD
ανά: Shosha, E, κ.ά.
Έκδοση: (2018)

The two faces of NMO
ανά: Schwarz, B, κ.ά.
Έκδοση: (2017)

Classifying the antibody-negative NMO syndromes: Clinical, imaging, and metabolomic modeling
ανά: Yeo, T, κ.ά.
Έκδοση: (2019)

METHOTREXATE MAY BE AN ALTERNATIVE TO AZATHIOPRINE IN NEUROMYELITIS OPTICA WITH AQUAPORIN-4 ANTIBODIES
ανά: Kitley, J, κ.ά.
Έκδοση: (2012)

Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays.
ανά: Waters, P, κ.ά.
Έκδοση: (2012)

Characterization of the Human NMO-1 gene at 1q43 and genomic organisation of the region. NMO-1.
ανά: Halford, S, κ.ά.
Έκδοση: (2000)

Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution.
ανά: Matthews, L, κ.ά.
Έκδοση: (2013)

Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease
ανά: Juryńczyk, M, κ.ά.
Έκδοση: (2016)

Seasonal pattern of variation in neuromyelitis optica relapses
ανά: Elsone, L, κ.ά.
Έκδοση: (2012)

Seroprevalence of NMO-IgG Antibody in Neuromyelitis optica (NMO) and Its Specificity in Differentiating NMO from Other Demyelinating Diseases with Overlap Symptoms: An Iranian Experience
ανά: Mohammad Hossein Harirchian, κ.ά.
Έκδοση: (2015-02-01)

Neuromyelitis Optica (NMO) — Study Review
ανά: Justyna Chojdak-Łukasiewicz
Έκδοση: (2021-06-01)

Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up.
ανά: Piccolo, L, κ.ά.
Έκδοση: (2016)

NMO-DBr: the Brazilian Neuromyelitis Optica Database System
ανά: Marco A. Lana-Peixoto, κ.ά.
Έκδοση: (2011-08-01)

An optimized immunohistochemistry technique improves NMO-IgG detection: study comparison with cell-based assays.
ανά: Romana Höftberger, κ.ά.
Έκδοση: (2013-01-01)

The clinical profile of NMOSD in Australia and New Zealand
ανά: Bukhari, W, κ.ά.
Έκδοση: (2020)

NMO in pediatric patients: brain involvement and clinical expression
ανά: Joaquín A. Peña, κ.ά.
Έκδοση: (2011-02-01)